Filter Results:
(333)
Show Results For
- All HBS Web (333)
- Faculty Publications (142)
Show Results For
- All HBS Web (333)
- Faculty Publications (142)
- Web
Rare Disease Day – Small Numbers, Big Challenges… and Big Opportunities - Blog: Health Supplement
cure or FDA approved treatment yet, and severe complications can arise if it is not properly diagnosed or treated. People living with rare diseases, like HHT, suffer from increased mortality and reduced quality of life , including higher... View Details
- Web
Globalization - Faculty & Research
case traces the evolution of the firm as it reinvents itself in response to the transformation of the CRO sector from a small, secondary cluster of firms into a major player with essential capabilities for global drug development. The... View Details
- 22 Aug 2005
- Research & Ideas
The Hard Work of Failure Analysis
analyzing failure benefit in two ways. First, analyzing a failed drug sometimes reveals that the drug may have a viable alternate use. For example, Pfizer's Viagra was originally designed to be a View Details
Keywords: by Amy Edmondson & Mark D. Cannon
- 01 Jun 2023
- News
From Big Pharma to Startup
the life cycle of the company”—from proof of concept to platform and product development. It plans to focus first on creating oral versions of peptide hormone drugs used to treat rare endocrine and metabolic diseases. Although Goble is no... View Details
Keywords: April White
- 25 Aug 2003
- Research & Ideas
Why IT Does Matter
Radio-frequency identification devices for grocery stores, smart cards, and automated ordering systems for hospital physicians are all examples of new process targets that technologies will soon address. In the more distant future we will see the improved creation of... View Details
Keywords: by F. Warren McFarlan & Richard L. Nolan
- 01 Jun 2004
- News
Working the Street
enough.” For Mike and other penitents among Los Angeles’s 100,000 gang members, the decision to remove gang-related tattoos, or “tats,” shows a fundamental commitment to change — the necessary laser treatments are lengthy, expensive,... View Details
- 06 Sep 2019
- Blog Post
The Business of Medicine: MD/MBA Students Having an Impact
the health, educational, and racial disparities exacerbated by poverty. “All the things you don’t associate with a Harvard Med student, I have seen and lived through,” he says, telling of close family members who have struggled with preventable infectious diseases,... View Details
- 31 Oct 2004
- Research & Ideas
Bypass Marketing: Are Docs Influenced?
drugs? How frequently do physicians prescribe advertised drugs when other drugs or treatments may be equally effective? We surveyed a national probability sample of 643... View Details
Keywords: by Manda Salls
- 01 Dec 2022
- News
Road to Recovery
withdrawal) and other incentives for remaining substance-free and engaging with a treatment program. The company currently offers programs for alcohol, opioids and heroin, and stimulant addiction. Participants can be prompted at random... View Details
- 01 Dec 2019
- News
The Race Against Resistance
and cancer. Antibiotics helped lift the average life expectancy at birth from 54 years in 1920 to 78.6 today. But almost as soon as the treatments were made available, physicians had to cope with the specter of antibiotic resistance, a... View Details
Keywords: Lisa Scanlon Mogolov
- 19 Sep 2016
- Research & Ideas
Why Isn't Business Research More Relevant to Business Practitioners?
disciplines, where academic research is leading to the development of a second skin that could improve drug delivery or alerting farmers and scientists on how to reduce nitrous oxide emissions from agricultural farming. Harvard Business... View Details
- 12 Jul 2020
- Research & Ideas
Solving COVID'S Mental Health Crisis
self-quarantine in sometimes unsafe home environments, anxiety about the virus and re-openings, and disconnection from treatment all are triggers and will contribute to substantial increases in substance use disorder (SUD) cases,... View Details
- 01 Dec 2013
- News
Your Own Medicine
WILLIAMS CHARLEY SECKLER in the midst of the first-ever trial for a DMD treatment at Johns Hopkins University. Photo courtesy the Seckler Family by Dan Morrell There's this picture of Charley Seckler from last summer that his mom has sent... View Details
- 01 Sep 2008
- News
Mara Aspinall
change that. Going forward, we need to view diagnostics, devices, and drugs in terms of the objective value that each creates. What about patient attitudes? Do you think most health-care consumers are ready to place their faith in View Details
- 15 Dec 2024
- News
After Ozempic
Back before Ozempic, when Kate Mulroney (MBA 1984) spoke at technical conferences about her work at Novo Nordisk, people often assumed she was talking about Novartis. “I’d have to explain that’s a Swiss company; we’re Danish,” says Mulroney, now head of advanced... View Details
- 07 Oct 2014
- News
Network Effect
after, because more genes with which to work would mean more avenues to explore in new drug development, exponentially increasing the chances of finding effective treatment and prevention. In 2004, the three... View Details
Keywords: Linda Kush
- 29 May 2001
- Research & Ideas
Genomics: Can We Start Making Money Now?
predict a new world where drug treatments are customized to an individual's genetic makeup, and gene-based therapy can root out cancer and other diseases before they take hold in the body. The new science... View Details
Keywords: by Sean Silverthorne
- 13 Jan 2003
- Research & Ideas
Making Biotech Work as a Business
technologies for drug discovery.) And patients with previously unmet medical needs can now get treatments that were not available before. That should be inspiring, he reminded the audience. Economic... View Details
- 07 Aug 2000
- Research & Ideas
The Business of Biotech
coming of age of biotechnology. The disappearance of "blockbuster" drugs could create new management challenges for pharmaceutical companies. — Gary Pisano The prospect is exhilarating, but the road to this brave new biotech... View Details
- 01 Jan 2009
- News
Kathryn E. Giusti, MBA 1985
organization, the Multiple Myeloma Research Consortium, have revolutionized cancer research. Under her leadership, the two groups have made incredible progress — including helping to bring patients four new treatments — and continue to... View Details